Hyundai Bioscience begins U.S. Phase 2 trial of Xafty for COVID, flu, and RSV
Hyundai Bioscience enters U.S. Phase 2 trials for Xafty, a broad-spectrum antiviral targeting flu, RSV, and COVID. Find out what this means for future pandemics.
Can AB-1009 reshape treatment for late-onset Pompe? AskBio prepares for first patient in U.S.
AskBio’s AB-1009 gene therapy for late-onset Pompe secures FDA IND clearance. Find out what this milestone means for AAV innovation and patient outlook.
TheraTears expands into digital eye strain relief: What the launch signals for OTC eye care
TheraTears adds eyelid wipes and preservative-free drops for screen fatigue. Find out what this expansion means for OTC dry eye care and consumer trends.
How Biocorneum’s new bruise kit reflects a wider shift in aesthetic medicine aftercare
Explore how Biocorneum’s dual-action bruise care system could reshape post-procedure recovery in aesthetic medicine. Read the strategic analysis now.
Ficlatuzumab joins Beat AML trial: is AVEO’s c-Met inhibitor ready for broader testing?
AVEO begins new trial of ficlatuzumab in front-line AML with Beat AML. Find out what this signals for older patients and c-Met inhibitor development.
Can Lynx Analytics’ Lumen framework reshape AI-driven decision-making in life sciences?
Lynx Analytics has introduced Lumen, a dedicated agentic artificial intelligence framework designed to support complex decision-making across life sciences workflows. The launch was anchored by a real-world deployment at AstraZeneca, where a custom-built application called IlluminAI is now embedded in the oncology team’s brand planning process across international markets. The framework is positioned as a […]
Cereno Scientific’s CS014 shows antithrombotic effect without bleeding risk in new HDAC study
Cereno Scientific has announced the peer-reviewed publication of its next-generation HDAC inhibitor CS014 in the Journal of Thrombosis and Haemostasis, revealing the compound’s ability to significantly reduce thrombosis without increasing bleeding risk. The study marks the first formal disclosure of CS014’s chemical structure and nonclinical pharmacology, positioning the compound as a differentiated HDAC inhibitor with […]
How annamycin’s clean cardiac safety profile may strengthen Moleculin’s oncology development strategy
Independent reviewers found no cardiotoxicity for Moleculin’s annamycin in 90 subjects. See how this safety milestone may reshape its oncology development path.
Why Creative Medical Technology Holdings’ ADAPT interim results may mark a turning point for cell-based chronic pain treatments
Find out how positive interim ADAPT trial data for CELZ-201 may signal a turning point in regenerative, non-opioid treatment approaches for chronic lower back pain.
Can Thryv’s SGK1 inhibitor become the first disease-modifying therapy for long QT syndrome type 2?
Thryv Therapeutics Inc. has initiated its pivotal Phase 2/3 Wave II clinical trial for THRV-1268, a novel orally administered SGK1 inhibitor, in adult patients with Long QT Syndrome Type 2 (LQTS2). The launch builds on promising results from the earlier Wave I study and a subsequent clinical investigation, both of which demonstrated meaningful QT interval […]